These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34999122)

  • 1. Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems.
    Hadji H; Bouchemal K
    Adv Drug Deliv Rev; 2022 Feb; 181():114101. PubMed ID: 34999122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral delivery systems for treatment of inflammatory bowel disease.
    Friend DR
    Adv Drug Deliv Rev; 2005 Jan; 57(2):247-65. PubMed ID: 15555741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
    Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
    Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives.
    Dos Santos AM; Carvalho SG; Meneguin AB; Sábio RM; Gremião MPD; Chorilli M
    J Control Release; 2021 Jun; 334():353-366. PubMed ID: 33901582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
    Kesisoglou F; Zimmermann EM
    Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Nanomedicine Ameliorates Acute Inflammatory Bowel Disease by Regulating Macrophages and T-Cells.
    Feng Z; Jiao L; Wu Z; Xu J; Gu P; Xu S; Liu Z; Hu Y; Liu J; Wu Y; Wang D
    Mol Pharm; 2021 Sep; 18(9):3484-3495. PubMed ID: 34310145
    [No Abstract]   [Full Text] [Related]  

  • 8. The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
    Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colon-targeted drug delivery of polysaccharide-based nanocarriers for synergistic treatment of inflammatory bowel disease: A review.
    Cui M; Zhang M; Liu K
    Carbohydr Polym; 2021 Nov; 272():118530. PubMed ID: 34420762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological variability and targeted delivery of therapeutics for inflammatory bowel diseases: an in silico approach.
    Haddish-Berhane N; Farhadi A; Nyquist C; Haghighi K; Keshavarzian A
    Inflamm Allergy Drug Targets; 2007 Mar; 6(1):47-55. PubMed ID: 17352688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease.
    Li DF; Yang MF; Xu HM; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Wang JY; Liang YJ; Yao J; Wang LS
    J Mater Chem B; 2022 Aug; 10(31):5853-5872. PubMed ID: 35876136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.
    Wolk O; Epstein S; Ioffe-Dahan V; Ben-Shabat S; Dahan A
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1275-86. PubMed ID: 23721560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.
    Chen F; Liu Q; Xiong Y; Xu L
    Int J Nanomedicine; 2021; 16():4225-4237. PubMed ID: 34188471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut.
    Fiorino G; Fries W; De La Rue SA; Malesci AC; Repici A; Danese S
    Curr Med Chem; 2010; 17(17):1851-7. PubMed ID: 20353384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives.
    Kotla NG; Rana S; Sivaraman G; Sunnapu O; Vemula PK; Pandit A; Rochev Y
    Adv Drug Deliv Rev; 2019 Jun; 146():248-266. PubMed ID: 29966684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in colonic drug delivery.
    Basit AW
    Drugs; 2005; 65(14):1991-2007. PubMed ID: 16162022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.